Key Takeaways
GLP-1 medications such as semaglutide can delay stomach emptying, meaning food may remain in the stomach longer than expected.
Residual food in the stomach may increase concern about aspiration during general anesthesia or deep sedation.
Current guidance favors an individualized approach rather than automatically stopping GLP-1 medications before every procedure.
Patients should tell the surgical and anesthesia team about their medication, dose, recent dose changes, and gastrointestinal symptoms before surgery.
GLP-1 medications have become increasingly familiar to patients living with type 2 diabetes or obesity. Drugs such as semaglutide help improve blood glucose control and may support weight management, but their effects on the digestive system have also raised an important question: What happens when a person taking a GLP-1 medication needs surgery?
For patients preparing for a procedure, the answer is not simply to stop the medication on their own.
Current recommendations emphasize that perioperative management should be tailored to each patient. The reason is that continuing the medication may raise concerns about delayed stomach emptying in some people, while stopping it — particularly in people with diabetes — may interfere with blood glucose management.
Why Can GLP-1 Medications Matter Before Surgery?
GLP-1 receptor agonists work in several ways. They help the body respond to blood glucose, reduce appetite, and can slow the movement of food from the stomach into the small intestine.
That last effect is particularly important before anesthesia.
Patients are normally instructed to stop eating and drinking for a certain period before surgery so that the stomach is as empty as possible. During general anesthesia or deep sedation, normal protective reflexes are reduced. If stomach contents move back up into the throat, they can potentially enter the lungs — a complication known as pulmonary aspiration.
GLP-1 medications have been associated with nausea, vomiting, and delayed gastric emptying, and studies have found that some people taking these medications may still have more material remaining in the stomach despite following standard fasting instructions. Cases of pulmonary aspiration have also been reported, although the exact degree of aspiration risk associated with GLP-1 therapy remains uncertain.
Do You Need to Stop Ozempic Before Surgery?
Not necessarily.
Earlier recommendations often advised patients to temporarily withhold GLP-1 medications before elective procedures. However, guidance has evolved as more evidence has become available.
The American Diabetes Association Standards of Care in Diabetes—2026 recommends a personalized approach. Factors such as why the medication is being used, blood glucose control, the medication and dose, gastrointestinal symptoms, the type and urgency of surgery, and the type of anesthesia should all be considered.
This means there is no single rule that applies to every patient.
Some people at relatively low risk for delayed gastric emptying may be able to continue their medication. For patients at greater risk, the healthcare team may consider additional precautions, such as a liquid diet before the procedure, assessing stomach contents with ultrasound, modifying the anesthesia plan, or temporarily withholding the medication.
Because recommendations can vary according to the patient and procedure, patients should not stop or change their GLP-1 medication without discussing it with the prescribing and surgical teams.
Who May Need Extra Attention?
Not everyone taking a GLP-1 medication has the same risk.
The surgical team may pay closer attention if a patient has symptoms suggesting delayed stomach emptying, such as:
persistent nausea,
vomiting,
abdominal bloating or distension,
indigestion or uncomfortable fullness, or
other symptoms suggesting that food is not moving normally through the stomach.
Medication history also matters. The healthcare team should know the exact medication being taken, how often it is used, the current dose, and whether the dose has recently changed.
These details help the team decide whether standard fasting instructions are sufficient or whether additional precautions are needed.
Why You Should Tell Your Nurse About GLP-1 Use
Medication reconciliation is an important part of nursing care before surgery.
During the preoperative assessment, nurses commonly review medications, fasting status, allergies, medical history, blood glucose levels, and current symptoms. For patients using GLP-1 therapy, accurate medication information can help the healthcare team identify possible perioperative risks early.
A patient should be prepared to tell the nurse:
What medication are you taking?
Know the name of the medication rather than simply saying that you take a “diabetes injection” or “weight-loss injection.”
When did you take your most recent dose?
Some GLP-1 medications are taken daily, while others are taken weekly.
Has your dose recently increased?
Changes in treatment may be relevant when the team evaluates gastrointestinal effects.
Are you experiencing nausea, vomiting, bloating, or unusual fullness?
Do not dismiss these symptoms simply because they seem mild.
Why are you taking the medication?
Management may differ depending on whether the medication is being used for diabetes, obesity treatment, or another clinical indication.
Sharing this information allows nurses, anesthesiologists, surgeons, and other healthcare professionals to plan care more safely.
What If You Take GLP-1 Medication for Diabetes?
There is another issue to consider: blood glucose control.
For people with diabetes, suddenly withholding a glucose-lowering medication may affect blood glucose levels. Surgery itself also places stress on the body, which can cause glucose levels to rise.
The ADA recommends monitoring blood glucose before, during, and after surgery, with a general perioperative target of 100–180 mg/dL (5.6–10.0 mmol/L), although targets may be individualized.
If a healthcare team decides that a GLP-1 medication should temporarily be withheld, another strategy may be needed to maintain appropriate glucose control. This is another reason why patients should not simply skip several doses without medical advice.
What Should You Do Before Your Procedure?
If you use Ozempic, Wegovy, another GLP-1 receptor agonist, or a related medication and have an upcoming procedure, preparation begins with communication.
Tell the surgical team about the medication as early as possible rather than waiting until the day of surgery. Follow the fasting or liquid-diet instructions given specifically for your procedure. Ask whether your medication schedule needs to change, particularly if you are unsure about your next dose.
Most importantly, report gastrointestinal symptoms before the procedure.
In some higher-risk situations, a 24-hour liquid nutrition protocol may be considered. Other professional guidance has also emphasized pre-procedure dietary modification as one strategy for reducing concern about retained stomach contents.
The exact plan should come from the healthcare team caring for you.
The Bottom Line
GLP-1 medications have changed the treatment of diabetes and obesity, but their increasing use has created new considerations for perioperative care.
The main concern before surgery is not the medication itself, but its potential effect on stomach emptying and how that may interact with anesthesia. At the same time, automatically stopping treatment is not always the safest solution, particularly for patients who depend on the medication for glucose management.
Today, perioperative care is moving toward a more individualized approach.
Before surgery, make sure your nurse, surgeon, anesthesiologist, and prescribing healthcare professional know that you are taking a GLP-1 medication. A short conversation about your medication, symptoms, and treatment schedule can help the healthcare team determine the safest plan for your procedure.
References
American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
American Diabetes Association Professional Practice Committee for Diabetes. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
Australian Diabetes Society, Australian and New Zealand College of Anaesthetists, Gastroenterological Society of Australia, and National Association of Clinical Obesity Services. Clinical Practice Recommendations on the Peri-Procedural Use of GLP-1/GIP Receptor Agonists. 2025.
Tidak ada komentar:
Posting Komentar